ABOUT THE SPEAKER:
Dr. McDonnell is a translational scientist who employs genetics, biochemistry, and chemical biology to probe the molecular mechanisms underlying the pathobiology of dysregulated hormone signaling in different cancers. His group discovered a new class of medicines (oral Selective Estrogen Receptor Downregulators; SERDs), thirteen of which are currently in clinical trials. Notable was his group’s discovery of Elacestrant (FDA approved January 2023) and Lasofoxifene (Phase II) as treatments for metastatic breast cancer. They are also developing new approaches to target the androgen signaling axis in metastatic castrate resistant prostate cancer. In recent years, his group has embarked on a major effort to understand how sex hormones impact tumor immunity through their ability to regulate immune cell repertoire and function. The clinical translation of insights from this work is a current focus of the group’s efforts. Dr. McDonnell and his team have also had a longstanding interest in defining the mechanisms by which hypercholesterolemia and dyslipidemia impact cancer biology.

HOST:
Prof David Virshup
Director
Programme in Cancer and Stem Cell Biology
Duke-NUS Medical School

DATE:
Wednesday, 15 March 2023

TIME:
10:30AM - 11:30AM

VENUE:
For in-person attendance:
Duke-NUS Medical School
Amphitheatre, Level 2

For virtual seminar (via Zoom), please register HERE.
(Please rename your login name to include your institution to facilitate admission)

CONTACT PERSON:
Ms Serene Wie (serene.wie@duke-nus.edu.sg)
Duke-NUS Research Affairs Department